Corey Goodman is a scientist, educator, and entrepreneur. He spent 25 years as Professor of Biology at Stanford University and Evan Rauch Chair of Neurobiology at U.C. Berkeley (Dept. of Molecular and Cell Biology), where he was a Howard Hughes Medical Institute Investigator, Head of the Neurobiology Division, and co-founder and Director of the Wills Neuroscience Institute. He is currently Adjunct Professor of Neuroscience in the Wills Neuroscience Institute at U.C. Berkeley.
Dr. Goodman is an elected member of the National Academy of Sciences, American Academy of Arts and Sciences, and American Philosophical Society, and recipient of many honors including the Alan T. Waterman Award, Canada Gairdner Biomedical Award, March-of-Dimes Prize in Developmental Biology, Reeve-Irvine Research Medal, and Dawson Prize in Genetics from Trinity College Dublin.
Dr. Goodman co-founded seven biotechnology companies (the first being Exelixis), and led one of them (Renovis) as President and CEO from a private to public company until its acquisition. He was recruited to be President and founder of Pfizer’s Biotherapeutics and Bioinnovation Center and a member of Pfizer’s executive leadership team.
Today Dr. Goodman is a Managing Partner of venBio Partners LLC. He is Chair of the Board of Solstice Biologics, Alexo Therapeutics, and Second Genome. He is a member of the Board of Checkmate and NFlection. He chaired Labrys Biologics until its acquisition by Teva. Amongst his many public policy roles, Dr. Goodman is Chair of the California Council on Science and Technology (advising the Governor and State Legislature), a member of the University of California Innovation Council, a member of the board of the Pacific Institute, and former Chair of the National Research Council's (NAS) Board on Life Sciences.